Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21064883 | 0.88 | DGAT1 (0.42) | DGAT1 | |
| SCHEMBL16661005 | 0.87 | DGAT1 (0.72) | DGAT1NPC1LMNANFKB1RAB9A | |
| SCHEMBL21064882 | 0.84 | DGAT1 (0.78) | DGAT1 | |
| SCHEMBL16661032 | 0.82 | DGAT1 (0.50) | DGAT1 | |
| SCHEMBL20428782 | 0.82 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL16661248 | 0.75 | DGAT1 (0.56) | DGAT1 | |
| SCHEMBL16660890 | 0.73 | DGAT1 (0.80) | DGAT1NPC1SMN1; SMN2 | |
| SCHEMBL21064830 | 0.73 | DGAT1 (0.46) | DGAT1 | |
| SCHEMBL16661013 | 0.71 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL16661026 | 0.71 | DGAT1 (1.00) | DGAT1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | DGAT1 1688/4885NPC1 796/4885LMNA 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.